Sha, Fushen http://orcid.org/0000-0003-3262-323X
Okwali, Michelle
Alperovich, Anna
Caron, Philip C.
Falchi, Lorenzo http://orcid.org/0000-0003-1531-3838
Hamilton, Audrey
Hamlin, Paul A.
Horwitz, Steven M.
Joffe, Erel http://orcid.org/0000-0002-7883-289X
Khan, Niloufer
Kumar, Anita
Matasar, Matthew J.
Moskowitz, Alison J.
Noy, Ariela http://orcid.org/0000-0002-3001-4898
Owens, Colette
Palomba, Lia M. http://orcid.org/0000-0001-5099-9156
Rodriguez-Rivera, Ildefonso
Straus, David
von Keudell, Gottfried
Zelenetz, Andrew D.
Yahalom, Joachim
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Schöder, Heiko
Seshan, Venkatraman E. http://orcid.org/0000-0002-9258-2698
Salles, Gilles http://orcid.org/0000-0002-9541-8666
Younes, Anas http://orcid.org/0000-0002-0001-4133
Batlevi, Connie L. http://orcid.org/0000-0002-9036-9463
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
Article History
Received: 15 September 2021
Revised: 12 January 2022
Accepted: 19 January 2022
First Online: 10 February 2022
Conflict of interest
: Fushen Sha: None. Michelle Okwali: None. Anna Alperovich: None. Philip C. Caron: None. Lorenzo Falchi: Research funding from Roche, Genmab; Consultancy for Genmab. Audrey Hamilton: None. Paul A. Hamlin: research support from Portola Pharmaceuticals, Molecular Templates, Incyte, and J&J Pharmaceuticals; and has a consultancy role with Portola Pharmaceuticals, Celgene, Karyopharm Therapeutics, and Juno Therapeutics. Steven M. Horwitz: research support from ADC Therapeutics, Aileron Therapeutics, Celgene, Forty Seven, Infinity Pharmaceuticals/Verastem Oncology, Kyowa Hakko Kirin, Millennium Pharmaceuticals/Takeda Oncology, Seattle Genetics, and Trillium; and has a consultancy role with ADC Therapeutics, Aileron, Corvus Pharmaceuticals, Forty Seven, Innate Pharma, Kyowa Hakko Kirin, Millennium/Takeda, Mundipharma, Portola, and Seattle Genetics. Erel Joffe: Advisory board: AstraZeneca, Epizyme. Niloufer Khan: Research funding from Seattle Genetics. Anita Kumar: research support from AbbVie, Adaptive Biotechnologies, Celgene, Pharmacyclics, and Seattle Genetics; and has an advisory role with Celgene. Matthew J. Matasar: research support from Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Rocket Medical, and Seattle Genetics; has received honoraria from Genentech, Roche, Bayer, Pharmacyclics, Janssen, Seattle Genetics, and GlaxoSmithKline; and has a consultancy role with Genentech, Bayer, Merck, Juno, Roche, Teva, Rocket Medical, and Seattle Genetics. Alison J. Moskowitz: research support from Incyte, Seattle Genetics, Bristol-Myers Squibb, and Merck; and has a consultancy role with Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC Therapeutics, Seattle Genetics, Cell Medica, Bristol-Myers Squibb, and Erytech Pharma. Ariela Noy: Research funding from Pharmacyclics, NIH, Raphael Pharma; consulting for Janssen, Pharmacyclics, Medscape, Targeted Oncology. Colette Owens: None. Lia M. Palomba: Honoraria from Merck, Celgene, Juno and Pharmacyclics. Ildefonso Rodriguez-Rivera: Stock/Ownership: Pfizer. David Straus: advisory role with Seattle Genetics. Gottfried von Keudell: has received research support from Pharmacyclics, Merck, Epizyme. Andrew D. Zelenetz: research support from MEI Pharma, MorphoSys, Sandoz, Celgene, Roche, and Gilead Sciences; has a consultancy role with Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, and Adaptive Biotechnologies; and serves on the board of directors (Data Monitoring Committee Chair) for BeiGene. Joachim Yahalom: none. Ahmet Dogan: personal fees from Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Takeda, Roche, EUSAPharma, PeerView, and research support from Roche and Takeda. Heiko Schoder: none. Venkatraman E. Seshan: none. Gilles Salles: consultancy role with Abbvie, Bayer, Beigene, BMS/Celgene, Debiopharm, Epizyme, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo, Milteniy, Morphosys, Novartis, Rapt, Regeneron, Takeda, Velosbio. Anas Younes: employment at AstraZeneca. Connie L. Batlevi: research support from Janssen, Novartis, Epizyme, Autolus, Roche, and Bayer; has received honoraria from Dava Oncology; and has a consultancy role with Skipta, Kite Pharma, MorphoSys, Bristol-Myers Squibb, Karyopharm Therapeutics, Genentech, and TG Therapeutics.